ARIAD Pharmaceuticals Inc logo

ARIA - ARIAD Pharmaceuticals Inc Share Price

$23.99 0.0  0.0%

Last Trade - 15/02/17

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £133.5m
Position in Universe th / 6643
Bullish
Bearish
Unlock ARIA Revenue
Momentum
Relative Strength (%)
1m -2.05%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 2016E 2017E CAGR / Avg
179 25.3 0.56 45.6 105.4 118.8 196.1 245 -7.9%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2016, AriadPharmaceuticals, Inc. revenues increased 82% to $149.7M.Net income totaled $28.2M vs. loss of $171.3M. Revenuesreflect Product revenue, net increase of 68% to $133.3M,License and other revenue increase from $3M to $16.5M. NetIncome reflects General and administrative - Balancing vdecrease of 12% to $89.4M (expense), Stock-basedCompensation in SGA decrease of 59% to $7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARIA Revenue Unlock ARIA Revenue

Net Income

ARIA Net Income Unlock ARIA Revenue

Normalised EPS

ARIA Normalised EPS Unlock ARIA Revenue

PE Ratio Range

ARIA PE Ratio Range Unlock ARIA Revenue

Dividend Yield Range

ARIA Dividend Yield Range Unlock ARIA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARIA EPS Forecasts Unlock ARIA Revenue
Profile Summary

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Directors
Last Annual December 31st, 2015
Last Interim September 30th, 2016
Incorporated April 12, 1991
Public Since May 20, 1994
No. of Shareholders: 288
No. of Employees: 459
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 194,200,862
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARIA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARIA
Upcoming Events for ARIA
Frequently Asked Questions for ARIAD Pharmaceuticals Inc
What is the ARIAD Pharmaceuticals Inc share price?

As of 15/02/17, shares in ARIAD Pharmaceuticals Inc are trading at $23.99, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the ARIAD Pharmaceuticals Inc share price performed this year?

Shares in ARIAD Pharmaceuticals Inc are currently trading at $23.99 and the price has moved by 0.394k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ARIAD Pharmaceuticals Inc price has moved by 0.280k% over the past year.

What are the analyst and broker recommendations for ARIAD Pharmaceuticals Inc?

Of the analysts with advisory recommendations for ARIAD Pharmaceuticals Inc, there are there are currently 1 "buy" , 7 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ARIAD Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will ARIAD Pharmaceuticals Inc next release its financial results?

ARIAD Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2017-09-30
What is the ARIAD Pharmaceuticals Inc dividend yield?

ARIAD Pharmaceuticals Inc does not currently pay a dividend.

Does ARIAD Pharmaceuticals Inc pay a dividend?

ARIAD Pharmaceuticals Inc does not currently pay a dividend.

When does ARIAD Pharmaceuticals Inc next pay dividends?

ARIAD Pharmaceuticals Inc does not currently pay a dividend.

How do I buy ARIAD Pharmaceuticals Inc shares?

To buy shares in ARIAD Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ARIAD Pharmaceuticals Inc?

Shares in ARIAD Pharmaceuticals Inc are currently trading at $23.99, giving the company a market capitalisation of £n/a.

Where are ARIAD Pharmaceuticals Inc shares listed? Where are ARIAD Pharmaceuticals Inc shares listed?

Here are the trading details for ARIAD Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ARIA
What kind of share is ARIAD Pharmaceuticals Inc?

We were not able to load our ranking data for ARIAD Pharmaceuticals Inc

Is there a ARIAD Pharmaceuticals Inc share price forecast 2021?

We were not able to load any forecast data for ARIAD Pharmaceuticals Inc.

How can I tell whether the ARIAD Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ARIAD Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 0.104k%. At the current price of $23.99, shares in ARIAD Pharmaceuticals Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ARIAD Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for ARIAD Pharmaceuticals Inc.

Who are the key directors of ARIAD Pharmaceuticals Inc?

We were unable to find the directors for ARIAD Pharmaceuticals Inc.

Who are the major shareholders of ARIAD Pharmaceuticals Inc?

Here are the top five shareholders of ARIAD Pharmaceuticals Inc based on the size of their shareholding:

Similar to ARIA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.